Olmesartan Medoxomil Eg

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomil Eg, is an Angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It treats hypertension and may be prescribed for adults requiring blood pressure control.

GNH USA supplies Olmesartan Medoxomil Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxil is an ARB that lowers blood pressure by blocking the renin‑angiotensin system. - Hypertension: helps achieve target blood pressure and reduces cardiovascular risk. - Diabetic nephropathy: slows progression of kidney damage associated with diabetes. - Heart failure: used as part of combination therapy to improve symptoms and outcomes.

Adverse reactions to olmesartan medoxil vary in frequency and severity.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Nasal congestion - Diarrhea - Cough

Serious or Rare Side Effects: - Angio‑edema involving the face, lips, tongue or airway - Severe hypotension - Acute kidney injury - Hyperkalemia - Liver enzyme elevations - Bullous pemphigoid skin eruption

When prescribing olmesartan medoxil, clinicians should consider several safety aspects. - Renal function monitoring: assess baseline creatinine and eGFR, then periodically. - Electrolyte balance: check serum potassium, especially if combined with potassium‑sparing diuretics. - Pregnancy: avoid use during the first trimester; discontinue if pregnancy is confirmed. - Concomitant NSAID therapy: may reduce antihypertensive effect and affect kidney function. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Olmesartan medoxil can interact with several medicines, requiring vigilance.

Major Interactions (Avoid): - Dual ARB/ACE‑inhibitor therapy: increased risk of renal dysfunction, hyperkalemia and hypotension. - Potassium‑rich supplements or salt substitutes: may cause dangerous hyper‑kalemia.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt blood‑pressure reduction and affect renal perfusion. - Diuretics (especially thiazides): may enhance hypotensive effect. - Lithium: olmesartan may increase lithium levels, risking toxicity. - Cyclosporine or tacrolimus: may raise serum creatinine. - Rifampicin: may reduce olmesartan plasma concentrations.